Carmustine medac (previously Carmustine Obvius) Europeiska unionen - bulgariska - EMA (European Medicines Agency)

carmustine medac (previously carmustine obvius)

medac gesellschaft für klinische spezialpräparate mbh - кармустином - hodgkin disease; lymphoma, non-hodgkin - Антинеопластични средства - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).

Rezolsta Europeiska unionen - bulgariska - EMA (European Medicines Agency)

rezolsta

janssen-cilag international n.v. - darunavir, кобицистат - ХИВ инфекции - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta е показан в комбинация с други антиретровирусни лекарствени продукти за лечение на инфекция с вируса на човешкия имунодефицитен вирус 1 (hiv 1) при възрастни на 18 или повече години. Генотипическое тестване трябва да се ръководите при използване на rezolsta.